- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Replimune Group, Inc. is seeking regulatory approval from the FDA for its therapies.
2 reports, 2 independent
Updated Aug 8
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Replimune Group, Inc. is seeking regulatory approval from the FDA for its therapies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The FDA issued a Complete Response Letter regarding the RP1 BLA to Replimune Group, Inc. on August 7, 2025.Sub-event
Replimune Group, Inc. filed for regulatory approval with the FDA.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Unregulated products are bypassing official government approval processes.
- FDA and Pfizer are seeking regulatory approval for their products.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
- The FDA granted QIDP designation to Talicia, an FDA-approved rifabutin-based product, on August 18, 2025. Rick Scruggs is President and CCO of RedHill Biopharma Ltd.
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- GlobeNewswireReplimune Announces Type A Meeting Scheduled with FDA WOBURN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the dev